Psychological therapies for preventing seasonal affective disorder.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
24 05 2019
Historique:
pubmed: 28 5 2019
medline: 11 9 2019
entrez: 25 5 2019
Statut: epublish

Résumé

Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on psychological therapies as preventive interventions. To assess the efficacy and safety of psychological therapies (in comparison with no treatment, other types of psychological therapy, second-generation antidepressants, light therapy, melatonin or agomelatine or lifestyle interventions) in preventing SAD and improving person-centred outcomes among adults with a history of SAD. We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 19 June 2018. An earlier search of these databases was conducted via the Cochrane Common Mental Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 August 2015). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature, Web of Science, the Cochrane Library, the Allied and Complementary Medicine Database and international trial registers (to 19 June 2018). We also conducted a grey literature search and handsearched the reference lists of included studies and pertinent review articles. To examine efficacy, we included randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared psychological therapy versus no treatment, or any other type of psychological therapy, light therapy, second-generation antidepressants, melatonin, agomelatine or lifestyle changes. We also planned to compare psychological therapy in combination with any of the comparator interventions listed above versus no treatment or the same comparator intervention as monotherapy. Two review authors screened abstracts and full-text publications against the inclusion criteria, independently extracted data, assessed risk of bias, and graded the certainty of evidence. We identified 3745 citations through electronic searches and reviews of reference lists after deduplication of search results. We excluded 3619 records during title and abstract review and assessed 126 articles at full-text review for eligibility. We included one controlled study enrolling 46 participants. We rated this RCT at high risk for performance and detection bias due to a lack of blinding.The included RCT compared preventive use of mindfulness-based cognitive therapy (MBCT) with treatment as usual (TAU) in participants with a history of SAD. MBCT was administered in spring in eight weekly individual 45- to 60-minute sessions. In the TAU group participants did not receive any preventive treatment but were invited to start light therapy as first depressive symptoms occurred. Both groups were assessed weekly for occurrence of a new depressive episode measured with the Inventory of Depressive Syptomatology-Self-Report (IDS-SR, range 0-90) from September 2011 to mid-April 2012. The incidence of a new depressive episode in the upcoming winter was similar in both groups. In the MBCT group 65% of 23 participants developed depression (IDS-SR ≥ 20), compared to 74% of 23 people in the TAU group (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.60 to 1.30; 46 participants; very low quality-evidence).For participants with depressive episodes, severity of depression was comparable between groups. Participants in the MBCT group had a mean score of 26.5 (SD 7.0) on the IDS-SR, and TAU participants a mean score of 25.3 (SD 6.3) (mean difference (MD) 1.20, 95% CI -3.44 to 5.84; 32 participants; very low quality-evidence).The overall discontinuation rate was similar too, with 17% discontinuing in the MBCT group and 13% in the TAU group (RR 1.33, 95% CI 0.34 to 5.30; 46 participants; very low quality-evidence).Reasons for downgrading the quality of evidence included high risk of bias of the included study and imprecision.Investigators provided no information on adverse events. We could not find any studies that compared psychological therapy with other interventions of interest such as second-generation antidepressants, light therapy, melatonin or agomelatine. The evidence on psychological therapies to prevent the onset of a new depressive episode in people with a history of SAD is inconclusive. We identified only one study including 46 participants focusing on one type of psychological therapy. Methodological limitations and the small sample size preclude us from drawing a conclusion on benefits and harms of MBCT as a preventive intervention for SAD. Given that there is no comparative evidence for psychological therapy versus other preventive options, the decision for or against initiating preventive treatment of SAD and the treatment selected should be strongly based on patient preferences and other preventive interventions that are supported by evidence.

Sections du résumé

BACKGROUND
Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on psychological therapies as preventive interventions.
OBJECTIVES
To assess the efficacy and safety of psychological therapies (in comparison with no treatment, other types of psychological therapy, second-generation antidepressants, light therapy, melatonin or agomelatine or lifestyle interventions) in preventing SAD and improving person-centred outcomes among adults with a history of SAD.
SEARCH METHODS
We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 19 June 2018. An earlier search of these databases was conducted via the Cochrane Common Mental Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 August 2015). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature, Web of Science, the Cochrane Library, the Allied and Complementary Medicine Database and international trial registers (to 19 June 2018). We also conducted a grey literature search and handsearched the reference lists of included studies and pertinent review articles.
SELECTION CRITERIA
To examine efficacy, we included randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. To examine adverse events, we intended to include non-randomised studies. We planned to include studies that compared psychological therapy versus no treatment, or any other type of psychological therapy, light therapy, second-generation antidepressants, melatonin, agomelatine or lifestyle changes. We also planned to compare psychological therapy in combination with any of the comparator interventions listed above versus no treatment or the same comparator intervention as monotherapy.
DATA COLLECTION AND ANALYSIS
Two review authors screened abstracts and full-text publications against the inclusion criteria, independently extracted data, assessed risk of bias, and graded the certainty of evidence.
MAIN RESULTS
We identified 3745 citations through electronic searches and reviews of reference lists after deduplication of search results. We excluded 3619 records during title and abstract review and assessed 126 articles at full-text review for eligibility. We included one controlled study enrolling 46 participants. We rated this RCT at high risk for performance and detection bias due to a lack of blinding.The included RCT compared preventive use of mindfulness-based cognitive therapy (MBCT) with treatment as usual (TAU) in participants with a history of SAD. MBCT was administered in spring in eight weekly individual 45- to 60-minute sessions. In the TAU group participants did not receive any preventive treatment but were invited to start light therapy as first depressive symptoms occurred. Both groups were assessed weekly for occurrence of a new depressive episode measured with the Inventory of Depressive Syptomatology-Self-Report (IDS-SR, range 0-90) from September 2011 to mid-April 2012. The incidence of a new depressive episode in the upcoming winter was similar in both groups. In the MBCT group 65% of 23 participants developed depression (IDS-SR ≥ 20), compared to 74% of 23 people in the TAU group (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.60 to 1.30; 46 participants; very low quality-evidence).For participants with depressive episodes, severity of depression was comparable between groups. Participants in the MBCT group had a mean score of 26.5 (SD 7.0) on the IDS-SR, and TAU participants a mean score of 25.3 (SD 6.3) (mean difference (MD) 1.20, 95% CI -3.44 to 5.84; 32 participants; very low quality-evidence).The overall discontinuation rate was similar too, with 17% discontinuing in the MBCT group and 13% in the TAU group (RR 1.33, 95% CI 0.34 to 5.30; 46 participants; very low quality-evidence).Reasons for downgrading the quality of evidence included high risk of bias of the included study and imprecision.Investigators provided no information on adverse events. We could not find any studies that compared psychological therapy with other interventions of interest such as second-generation antidepressants, light therapy, melatonin or agomelatine.
AUTHORS' CONCLUSIONS
The evidence on psychological therapies to prevent the onset of a new depressive episode in people with a history of SAD is inconclusive. We identified only one study including 46 participants focusing on one type of psychological therapy. Methodological limitations and the small sample size preclude us from drawing a conclusion on benefits and harms of MBCT as a preventive intervention for SAD. Given that there is no comparative evidence for psychological therapy versus other preventive options, the decision for or against initiating preventive treatment of SAD and the treatment selected should be strongly based on patient preferences and other preventive interventions that are supported by evidence.

Identifiants

pubmed: 31124141
doi: 10.1002/14651858.CD011270.pub3
pmc: PMC6533196
doi:

Substances chimiques

Antidepressive Agents 0
Melatonin JL5DK93RCL

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD011270

Commentaires et corrections

Type : UpdateOf

Références

CNS Spectr. 2005 Aug;10(8):635-46; quiz 1-14
pubmed: 16041295
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Cochrane Database Syst Rev. 2019 Mar 18;3:CD011269
pubmed: 30883670
J Affect Disord. 2014 Oct;168:205-9
pubmed: 25063959
J Clin Psychol. 2012 Feb;68(2):179-86
pubmed: 23616298
Lancet. 1998 Oct 24;352(9137):1369-74
pubmed: 9802288
Lancet. 2011 Aug 13;378(9791):621-31
pubmed: 21596429
Eur Arch Psychiatry Clin Neurosci. 2005 Apr;255(2):75-82
pubmed: 15812600
Science. 1987 Jan 16;235(4786):352-4
pubmed: 3798117
J Consult Clin Psychol. 2003 Feb;71(1):22-30
pubmed: 12602422
BMJ. 2010 May 21;340:c2135
pubmed: 20495016
BMC Psychiatry. 2018 Nov 26;18(1):372
pubmed: 30477472
Diabetes Care. 2014 Sep;37(9):2427-34
pubmed: 24898301
Psychol Med. 1999 Jul;29(4):869-78
pubmed: 10473314
Am J Psychiatry. 2015 Sep 1;172(9):862-9
pubmed: 25859764
Am J Psychiatry. 2016 Mar 1;173(3):244-51
pubmed: 26539881
Behav Ther. 2009 Sep;40(3):225-38
pubmed: 19647524
Psychol Psychother. 2007 Jun;80(Pt 2):217-28
pubmed: 17535596
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD008591
pubmed: 22161433
Int J Neuropsychopharmacol. 2001 Dec;4(4):409-20
pubmed: 11806867
Am J Psychiatry. 2006 May;163(5):805-12
pubmed: 16648320
Cochrane Database Syst Rev. 2019 Mar 18;3:CD011268
pubmed: 30883669
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
J Affect Disord. 1998 Jul;50(1):59-64
pubmed: 9716282
Am J Psychiatry. 1996 Aug;153(8):1028-36
pubmed: 8678171
CNS Spectr. 2005 Aug;10(8):647-63; quiz 672
pubmed: 16041296
Cochrane Database Syst Rev. 2015 Nov 11;(11):CD011270
pubmed: 26560172
Psychiatry Res. 1990 Feb;31(2):131-44
pubmed: 2326393
Am Fam Physician. 2012 Dec 1;86(11):1037-41
pubmed: 23198671
Dialogues Clin Neurosci. 2007;9(3):315-24
pubmed: 17969868
Biol Psychiatry. 2005 Oct 15;58(8):658-67
pubmed: 16271314
J Consult Clin Psychol. 2007 Jun;75(3):489-500
pubmed: 17563165
Am Psychol. 2006 Nov;61(8):774-788
pubmed: 17115810
Neuroscience. 2011 Dec 1;197:8-16
pubmed: 21963350
Cochrane Database Syst Rev. 2015 Nov 11;(11):CD011271
pubmed: 26560173
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Expert Opin Investig Drugs. 2012 Oct;21(10):1503-22
pubmed: 22876742
Arch Gen Psychiatry. 1984 Jan;41(1):72-80
pubmed: 6581756
Trials. 2013 Mar 21;14:82
pubmed: 23514124
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
CNS Spectr. 2005 Aug;10(8):625-34; quiz 1-14
pubmed: 16041294
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
CNS Drugs. 2007;21(11):901-9
pubmed: 17927295
J Affect Disord. 2004 Jun;80(2-3):273-83
pubmed: 15207942
J Consult Clin Psychol. 2006 Apr;74(2):367-376
pubmed: 16649881
BMC Psychiatry. 2017 Jul 11;17(1):247
pubmed: 28693583
Psychol Bull. 1987 Mar;101(2):259-82
pubmed: 3562707
Biol Psychiatry. 1999 Jul 15;46(2):239-46
pubmed: 10418699
Am J Psychiatry. 1998 Mar;155(3):428-30
pubmed: 9501759
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Cognit Ther Res. 2013 Dec;37(6):
pubmed: 24415812

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH